Barclays PLC Purchases 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Barclays PLC raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 19.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 459,521 shares of the company's stock after acquiring an additional 75,609 shares during the quarter. Barclays PLC owned approximately 0.06% of Roivant Sciences worth $5,302,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Clearbridge Investments LLC grew its position in Roivant Sciences by 51.3% in the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company's stock valued at $19,666,000 after purchasing an additional 630,712 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Roivant Sciences by 40.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company's stock worth $6,840,000 after buying an additional 185,226 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of Roivant Sciences in the third quarter valued at about $2,267,000. TOMS Capital Investment Management LP bought a new stake in Roivant Sciences during the third quarter worth about $46,333,000. Finally, Loomis Sayles & Co. L P boosted its position in Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after purchasing an additional 458,601 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ROIV. Cantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. Finally, Bank of America boosted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.93.

Roivant Sciences Trading Up 0.6 %

ROIV stock traded up $0.07 during mid-day trading on Friday, hitting $11.57. 15,754,118 shares of the company were exchanged, compared to its average volume of 5,795,466. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The stock has a market capitalization of $8.42 billion, a PE ratio of 2.05 and a beta of 1.25. The business has a 50 day simple moving average of $11.91 and a 200-day simple moving average of $11.48.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the sale, the chief operating officer now owns 606,525 shares in the company, valued at $6,865,863. The trade was a 14.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of the business's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now directly owns 17,870,543 shares of the company's stock, valued at $210,693,701.97. This represents a 9.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,089,893 shares of company stock worth $48,254,821. Company insiders own 7.90% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.